%0 Journal Article
%T Advances in the Research of Long Life<br>长效重组蛋白药物的研究进展
%A QI Nan
%A MA Qing-jun
%A <br>戚楠
%A 马清钧
%J 中国生物工程杂志
%D 2006
%I 
%X The recombinant protein drug usually has a short half-life after intravenous (IV) or subcutaneous (SC) administration. The methods of prolonging the half-life of recombinant protein drug in common use are mainly based on three principles: 1 Amplifying the molecule weight of protein drug; 2 Making use of drug balance in the blood; 3 Reducing Immunogenicity. Three methods were focused on: Analog construction, PEGylation and Albumin fusion technology. The characteristics, half-life and immunogenicity problem of their products in the market and under development are summarized.
%K Long life recombinant protein drug Half life Molecule weight Drug balance Immunogenicity Analog PEGlyation Albumin fusion<br>长效重组蛋白药物
%K 半衰期
%K 分子量
%K 药物平衡
%K 免疫原性
%K 突变体
%K PEG化
%K 血清白蛋白
%U http://www.alljournals.cn/get_abstract_url.aspx?pcid=90BA3D13E7F3BC869AC96FB3DA594E3FE34FBF7B8BC0E591&jid=951380788B355DEA7D75520FA3B199C9&aid=D13BD6D5139FF478&yid=37904DC365DD7266&vid=96C778EE049EE47D&iid=0B39A22176CE99FB&sid=9C65ADEB5990B252&eid=0D0D661F0B316AD5&journal_id=1671-8135&journal_name=中国生物工程杂志&referenced_num=18&reference_num=24